Home Telemonitoring In Patients After Myocardial Infarction


About this study

The purpose of this study is to evaluate patients undergoing cardiac catheterization. The hypothesis is that patients who go home with 12 lead ECG home telemonitoring will have decreased general and cardiac ED presentation and hospital readmission rates without an increase in major adverse cardiac events and at a lower health care utilization cost compared to patients with standard therapy alone.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥ 18 years of age.
  • Acute myocardial infarction, STEMI and NSTEMI.
  • Ability to use the device at home.
  • Must have smartphone device with home wi-fi/internet available which allow 24-7 ability to transmit ECG.
  • Caring family member who will be able to perform the ECG in case the patient himself/herself won't be able to do it.

Exclusion Criteria:

  • No ability to use the device at home.
  • No smartphone device or home wi-fi/mobile internet which prevent 24/7 ability to transmit ECG.
  • Cannot download the smartheart app.
  • No support in home environment.
  • Out of hospital cardiac arrest: secondary to a non-shockable rhythm, unrelated to an acute coronary syndrome, or with any level of neurologic damage.
  • Resident of nursing home or acute care facility
  • Uninterpretable ECG at discharge – left bundle branch block (LBBB), pacemaker or implantable cardioverter defibrillator (ICD) with pacing dependence.
  • Patients who are planned for staged PCI after the index hospitalization.

Eligibility last updated 1/13/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Joerg Herrmann, M.D.

Open for enrollment

Contact information:

Sarah Devamani

(507) 255-0876


More information


Publications are currently not available

Mayo Clinic Footer